Our research focus

Product pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Tregalizumab (BT-061) - other diseases
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information